CD19 and neoplasm: Measurements of tumor volumes showed that tumors in the high-dose CD19pbCAR T-cell group were much smaller than tumors in the other groups, indicating that CD19pbCAR T cells can effectively eliminate CD19+ tumor cells (Figure 5D).